Literature DB >> 18455693

Latinos and chronic hepatitis C: a singular population.

Maribel Rodríguez-Torres1.   

Abstract

Latinos are the largest minority in the USA and have higher rates of HCV infection. The course of chronic hepatitis C in Latinos is more aggressive, with higher risk to develop cirrhosis than any other ethnic group or race. Available information suggests that more rapid progression of liver disease is aggravated by decreased efficacy to treatment with available therapies. The causes for more aggressive progression and decreased efficacy of treatment are complex. Factors related to metabolic syndrome, insulin resistance, and hepatic steatosis are important, as well as genetic differences, not only for metabolic syndrome but for immune responses to interferon. In addition, there are substantial barriers for Latinos to access medical care. Language, cultural differences, and socioeconomic factors, including lack of medical insurance, more frequent use of alcohol, and possible medical care provider bias, are significant obstacles to diagnosis and treatment. The severity of the liver disease and the association to metabolic syndrome medical conditions justify that Latinos be considered a special population with urgent need of intervention strategies. In this article we present all the available evidence on epidemiology, natural history of chronic hepatitis C, and efficacy of anti-HCV therapy in Latinos infected with HCV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455693     DOI: 10.1016/j.cgh.2008.02.036

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  9 in total

1.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

2.  Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection.

Authors:  Blaire E Burman; Peter Bacchetti; Claudia E Ayala; Nicholas Gelman; Jennifer Melgar; Mandana Khalili
Journal:  Liver Int       Date:  2014-09-20       Impact factor: 5.828

3.  Impact of Moderate Alcohol Discontinuation on Insulin Action and Secretion in Latinos With and Without Hepatitis C.

Authors:  Lindsay A Uribe; Peter Bacchetti; Nicholas Gelman; Esteban Burchard; Mark Fitch; Marc Hellerstein; Mandana Khalili
Journal:  Alcohol Clin Exp Res       Date:  2018-02-01       Impact factor: 3.455

4.  Hepatitis C Infection Among Hispanics in California.

Authors:  Catherine A Cummins; Erlyana Erlyana; Dennis G Fisher; Grace L Reynolds
Journal:  J Addict Dis       Date:  2015

5.  Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.

Authors:  Rebecca G Kim; Jonathan Kramer-Feldman; Peter Bacchetti; Barbara Grimes; Esteban Burchard; Celeste Eng; Donglei Hu; Marc Hellerstein; Mandana Khalili
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

6.  A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.

Authors:  Jorge Méndez-Navarro; Ruby A Chirino; Kathleen E Corey; Emmanuel C Gorospe; Hui Zheng; Segundo Morán; Jesus A Juarez; Raymond T Chung; Margarita Dehesa-Violante
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

7.  Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.

Authors:  Rania A Tohme; Jian Xing; Youlian Liao; Scott D Holmberg
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

Review 8.  Natural History of Hepatitis C.

Authors:  Shilpa Lingala; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2015-08-25       Impact factor: 3.806

9.  Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley.

Authors:  Muhammad Y Sheikh; Pradeep R Atla; Adnan Ameer; Humaira Sadiq; Patrick C Sadler
Journal:  Gut Liver       Date:  2012-12-14       Impact factor: 4.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.